State ADAPs Ask Manufacturers For Price Concessions; Fuzeon Fuels Effort
Executive Summary
State AIDS Drug Assistance Programs are asking all HIV therapy manufacturers for price breaks as they prepare to pick up coverage of Roche's Fuzeon
You may also be interested in...
State ADAPs secure higher Rx discounts
Abbott, Boehringer Ingelheim, Gilead and Merck agree to price concessions for state AIDS drug assistance programs. Abbott agreement provides supplemental rebates on full HIV/AIDS product line; BI says it will freeze Viramune price for two years. Companies join Roche in finalizing negotiations following Washington, D.C. meeting (1"The Pink Sheet" April 21, p. 7). Discussions with Pfizer/Agouron, GlaxoSmithKline and Bristol-Myers Squibb are ongoing, state directors say...
State ADAPs secure higher Rx discounts
Abbott, Boehringer Ingelheim, Gilead and Merck agree to price concessions for state AIDS drug assistance programs. Abbott agreement provides supplemental rebates on full HIV/AIDS product line; BI says it will freeze Viramune price for two years. Companies join Roche in finalizing negotiations following Washington, D.C. meeting (1"The Pink Sheet" April 21, p. 7). Discussions with Pfizer/Agouron, GlaxoSmithKline and Bristol-Myers Squibb are ongoing, state directors say...
Roche Fuzeon WAC
Wholesale acquisition cost of Roche/Trimeris' HIV agent Fuzeon (enfuvirtide) will be "just under $20,000 for one year's supply," the companies said. Roche Global Pharmaceutical Head William Burns said a settlement has been reached with state AIDS Drug Assistance Programs but "it is on terms that we are not releasing publicly." Roche used its broad antiretrovial portfolio as leverage in price negotiations with state ADAPs (1"The Pink Sheet" March 24, p. 35)...